ARCA biopharma Inc. (NASDAQ: ABIO) Featured in Coverage of Investor Summit Group’s Q3 Virtual Event
ARCA biopharma Inc. (NASDAQ: ABIO) is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing rNAPc2 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. The U.S. FDA has granted Fast Track designation to the rNAPc2 development program, currently in Phase 2b clinical testing and an Orphan Drug designation…